ADC Development

How this supports a project

ADC material planning must connect the antibody conjugation site, reactive handle, linker architecture, payload properties, target loading, stability, release concept, and analytical strategy.

Linker and conjugation site must be considered together

An ADC linker is not selected by a cleavable or non-cleavable label alone. Conjugation site, antibody modification method, reactive handle, payload hydrophobicity, spacer, target drug-to-antibody ratio, and release mechanism together affect the physicochemical and biological properties of the final conjugate.

Published site-specific ADC studies show that changing either the conjugation site or linker structure can change stability and other ADC characteristics. A linker-payload intermediate should therefore be defined for a specific conjugation strategy and analytical plan.

How material decisions enter the program

Define the antibody-side chemistry

Specify native or engineered residue, conjugation site, modification method, reactive group, and target loading.

Define the payload-side requirements

Record the payload identity or reference structure, attachment position, functional group, hydrophobicity constraints, and stability concerns.

Choose the release concept

Define stable or cleavable architecture and, for cleavable designs, the proposed trigger and resulting released species.

Design spacer and conjugation handle

Select spacer length and hydrophilicity plus maleimide, haloacetamide, NHS, click, enzymatic, or other strategy compatible with the antibody platform.

Prepare and characterize the intermediate

Confirm structure, stereochemistry where applicable, identity, purity, residual reagents, and storage stability of the linker or linker-payload material.

Evaluate the complete conjugate

Measure conjugation site or distribution, loading, free payload, aggregation, purity, stability, and biological performance using the intended antibody system.

What to define before an inquiry

Antibody conjugation strategy

State lysine, cysteine, engineered site, enzymatic tag, glycan, or other method and the available reactive handle.

Payload definition

Provide exact identity or structure, attachment site, functional group, and any handling constraints; payload availability is confirmed separately.

Linker architecture

Specify release motif, spacer, hydrophilic elements, branching, handle, and expected released species.

Target loading and heterogeneity

Define the intended drug-to-antibody ratio and whether a distribution or site-specific homogeneous conjugate is expected.

Analytical plan

Set methods for intermediate identity and purity and for final-conjugate loading, free payload, aggregation, stability, and site confirmation.

Application boundary

This page covers linker, spacer, handle, and conjugation-ready intermediate planning. It does not imply antibody engineering, ADC manufacture, payload availability, a target drug-to-antibody ratio, biological efficacy, safety, clinical suitability, or regulatory status. Payload and project scope are confirmed case by case.

Related catalog and technical pages

ADC linkers and conjugation reagentsBrowse cleavable and stable linkers, hydrophilic spacers, reactive handles, and related intermediates.ADC linker-payload chemistryReview the site scope for linker architecture, conjugation-ready intermediates, and payload-specific project review.Conjugation chemistry and linkersReview functional handles, spacer design, stable or cleavable linkages, and analytical questions.Click chemistry and bioconjugation reagentsBrowse DBCO, BCN, azide, tetrazine, NHS ester, maleimide, and other conjugation handles.Cleavable versus non-cleavable linkersReview the project questions that distinguish stable and release-triggered linker strategies.